Companion Animal Diagnostics Market: as pet humanisation pushes veterinary medicine toward the same multi-modality, AI-assisted diagnostic standard pet owners expect from their own healthcare, IDEXX's slide-free cellular analyzer and Mars' cross-border laboratory consolidation redefine what a routine veterinary visit looks like, so instrument placement deepens per-visit test revenue above the underlying visit volume growth rate, and the oncology screening category creates a premium pricing tier that did not structurally exist in companion animal diagnostics until the 2024 to 2025 product launch cycle.

The global companion animal diagnostics market size was USD 8.80 Billion in 2025 and is expected to register a revenue CAGR of 9.8% during the forecast period. Market revenue growth is driven by factors such as sustained pet ownership expansion and rising veterinary care medicalisation rates, IDEXX Laboratories' premium instrument installed base expansion generating recurring consumable revenue above underlying clinic visit volume growth, and the launch of in-clinic oncology screening products creating a new high-value diagnostic revenue category. The first driving factor is sustained pet ownership expansion and rising veterinary care medicalisation across major markets. The American Pet Products Association reported that US pet-owning households rose to nearly 94 million in 2024, up from approximately 85 million in 2019, while the United Kingdom's Pet Food Manufacturers' Association reported that more than 57% of UK households owned pets in 2024, establishing the demographic base underlying sustained diagnostic testing volume growth. The second driving factor is IDEXX's premium instrument installed base expansion generating per-visit test revenue above the underlying visit volume growth. IDEXX reported full-year 2024 Companion Animal Group revenue of USD 3.57 Billion, representing 92% of total company revenue, with IDEXX VetLab consumables generating 12% reported and organic revenue growth in Q4 alongside global premium instrument installed base growth and net price gains. The third driving factor is Zoetis's companion animal portfolio expansion, with full-year 2024 revenue of USD 9.30 Billion and Companion Animal segment revenue growing at double-digit rates through osteoarthritis pain products and diagnostics investment. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way point-of-care testing performed at the time and location the pet receives care compounds per-visit diagnostic revenue as the instrument testing menu per visit expands through premium platform placements, without requiring any change in total veterinary clinic visit volume. Once a veterinary clinic installs the IDEXX VetLab Suite, inVue Dx Cellular Analyzer, and Cancer Dx oncology screening alongside its existing infectious disease SNAP panel, each annual wellness visit generates diagnostic revenue across four distinct instrument categories simultaneously, so the per-visit diagnostic revenue compounds as the multi-instrument footprint per clinic deepens regardless of whether the total visit count grows. As a result, demand and revenue share are concentrating around IDEXX and Mars/Antech whose combined premium instrument depth per clinic site and reference laboratory service breadth creates revenue streams that single-category instrument manufacturers and independent point-of-care device companies cannot match, and the forecast tilts toward these multi-instrument integrated platform incumbents rather than standalone chemistry analyzer or hematology device companies. For instance, in September 2024, Mars acquired SYNLAB Vet to expand its European veterinary diagnostics capabilities with advanced diagnostics, imaging, and telemedicine, adding to its existing Antech, Banfield, BluePearl, VCA, SOUND, and AniCura portfolio, one of more than a dozen strategic moves both companies have made in the 2024 to 2025 period to extend their integrated platform depth into new diagnostic categories and geographic markets. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is IDEXX's extension of its multi-instrument premium platform strategy into the oncology and slide-free cellular analysis categories, which create a new, higher per-test consumable revenue tier at veterinary clinics that adds to existing chemistry and hematology instrument revenue without replacing it. Premium oncology instrument extension works as a compounding demand driver because pet-owner willingness to pay for oncology diagnostic services is structurally higher than for routine wellness chemistry panels, allowing IDEXX to sustain premium pricing for Cancer Dx and inVue Dx consumables above its established chemistry and hematology reagent price schedules, so the per-practice diagnostic revenue uplift from oncology instrument adoption is proportionally larger than the uplift from adding an additional chemistry or hematology platform. IDEXX began shipping its inVue Dx Cellular Analyzer, described as transformational by CEO Jay Mazelsky, during the fourth quarter of 2024, with the company confirming nearly 700 pre-orders of the platform ahead of shipment and noting that customers especially value solutions like inVue Dx that provide meaningful clinical insights while giving time back to busy veterinary practice staff. IDEXX confirmed plans to make Cancer Dx screening for canine lymphoma available in the United States and Canada by late March 2025, and the American Pet Products Association's data showing US pet-owning households grew to nearly 94 million in 2024 confirms the demographic base supporting sustained diagnostic testing volume growth at the veterinary clinics serving this expanded pet ownership base. The effect on the market is a structural per-practice revenue uplift at every clinic that adopts inVue Dx or Cancer Dx on top of its existing VetLab instrument suite, creating a diagnostic revenue growth rate above same-store visit volume growth as the multi-instrument footprint deepens per clinic location. These are some of the key factors driving revenue growth of the market.

The second driver is Mars's systematic parallel strategy of direct reference laboratory capacity acquisition and partnership-based oncology test menu expansion, which simultaneously expands the Mars/Antech geographic reach in European reference laboratory markets while diversifying the oncology testing menu available to Antech-partner veterinary clinics without requiring internal assay development timelines. Mars's dual strategy works as a demand driver because the SYNLAB Vet acquisition converts European reference laboratory volumes immediately onto the Mars/Antech platform while the VolitionRx Nu.Q Vet Cancer Test partnership provides an immediately deployable oncology screening product at Antech-connected clinics across North America and Europe without the multi-year internal assay development, validation, and FDA/USDA submission timeline that internal product development would require. In September 2024, Mars acquired SYNLAB Vet, expanding the company's European veterinary diagnostics capabilities with advanced diagnostics, imaging, and telemedicine solutions, adding to its existing portfolio of Antech, Banfield, BluePearl, VCA, SOUND, and AniCura. In April 2024, VolitionRx launched its Nu.Q Vet Cancer Test in US and European veterinary clinics through Antech, enabling rapid six-minute in-clinic canine cancer screening on the Element i+ Analyzer, providing a cost-effective early cancer detection tool for high-risk breeds and senior dogs and directly competing with IDEXX's Cancer Dx in the in-clinic oncology screening category. The effect on the market is an accelerating competitive race between IDEXX and Mars/Antech specifically in the oncology screening and European reference laboratory segments, with both companies making their most consequential 2024 strategic moves in precisely those two areas. These are some of the key factors driving revenue growth of the market.

"IDEXX VetLab consumables generating 12% reported and organic revenue growth in Q4 2024 while same-store clinical visit growth moderated confirms the structural reality of the premium instrument installed base model. The revenue compounds above the visit volume rate because each instrument placement deepens the test menu per visit rather than requiring more visits to generate more revenue. The oncology screening category adds a third compounding dimension: not just more instruments per practice, but instruments in a category where pet-owner willingness to pay is structurally higher per test than in routine wellness chemistry."

Clarivant Analyst Intelligence, Q1 2026

The third driver is the sustained expansion of the companion animal population and the rising medicalisation of veterinary care in Asia Pacific markets, particularly China, where urban pet ownership growth and increasing per-visit diagnostic testing intensity are simultaneously expanding both the population-level and per-patient dimensions of the total addressable diagnostic market. Structural medicalisation works as a sustained driver because it involves permanent upward shifts in pet-owner behaviour and expectation levels rather than cyclical changes, so the testing intensity per veterinary visit compounds permanently upward as pet owners in newly medicalising markets converge toward the multi-test per visit norm that characterises mature North American companion animal diagnostics markets. IDEXX confirmed double-digit international CAG Diagnostics recurring revenue growth throughout 2024 with Asia Pacific identified as a primary international growth contributor, and Zoetis reported double-digit Companion Animal segment revenue growth through its reference laboratory services portfolio in Asia Pacific. The American Pet Products Association data showing a nine-million-household increase in US pet-owning households between 2019 and 2024 and the UK Pet Food Manufacturers' Association reporting 57% UK household pet ownership in 2024 confirm that pet ownership expansion is not limited to emerging markets but continues to provide incremental volume tailwinds even in the most mature companion animal diagnostics markets globally. The effect on the market is a geographic diversification of the companion animal diagnostics revenue base that reduces dependence on North American same-store visit volume growth as the primary market driver over the forecast period. These are some of the key factors driving revenue growth of the market.

However, the companion animal diagnostics market faces adoption constraints from the high cost of comprehensive diagnostic workups relative to the low pet insurance penetration rate and from the veterinary technician workforce shortage constraining clinic throughput capacity. Because comprehensive diagnostic workups can cost USD 500 to USD 1,500 or more per visit at specialist veterinary hospitals, and less than 4% of US pet owners carry veterinary insurance, the vast majority of companion animal diagnostic revenue depends on direct pet-owner out-of-pocket payment that creates price sensitivity dynamics fundamentally different from the reimbursement-insulated human diagnostics market, so companion animal diagnostics companies cannot rely on the net price realisation leverage that human diagnostic companies sustain through third-party reimbursement frameworks. Veterinary technician workforce shortage compounds this, since the American Veterinary Medical Association identified technician shortages as among the most significant operational constraints facing veterinary practices in 2024, and clinics operating below optimal staffing levels cannot fully utilise their installed diagnostic instrument capacity, limiting the rate at which IDEXX premium instrument placements translate into actual test volume growth at individual practice locations even after instrument placement investment has been completed. High instrument capital cost creates a third constraint for smaller independent veterinary practices, since IDEXX VetLab premium instrument suites including the Catalyst One, ProCyte Dx, and inVue Dx represent multi-thousand-dollar upfront investment or multi-year placement fee commitments that independent single-location practices must weigh against uncertain volume return, so the premium instrument penetration ceiling for single-location independent practices is lower than for corporate veterinary group practices that can spread the instrument capital cost and consumable commitment across a larger patient volume base. These factors substantially limit companion animal diagnostics market growth over the forecast period.

Based on product and service, the global companion animal diagnostics market is segmented into instruments and point-of-care analyzers, consumables and reagents, and reference laboratory services. Consumables and reagents holds the largest revenue share, because the recurring reagent consumption model tied to each installed premium VetLab and point-of-care instrument generates predictable per-test revenue that compounds in absolute terms as the installed instrument base grows, and the closed-system reagent exclusivity provisions in IDEXX's instrument placement contracts concentrate consumable revenue at IDEXX across its installed base even as the instruments themselves age through their useful lives. Instruments and point-of-care analyzers represent the second revenue category, capturing hardware placement and annual service contract revenues. Reference laboratory services is expected to register the fastest revenue growth rate in the global companion animal diagnostics market over the forecast period, driven by Mars's September 2024 SYNLAB Vet acquisition expanding European reference laboratory capacity, the growth of specialist cytopathology and oncology testing referral volumes, and IDEXX's established reference laboratory network expansion alongside its in-clinic platform.

Based on animal type, the global companion animal diagnostics market is segmented into dogs, cats, and horses and other companion animals. Canine testing holds the largest revenue share, reflecting the larger global population of pet dogs relative to cats in most major markets, the broader range of diagnostic testing performed across canine wellness, chronic disease management, and oncology screening, and the canine-first product development strategy that IDEXX Cancer Dx, Antech Nu.Q Vet Cancer Test, and Oxford BioDynamics EpiSwitch SCB have all followed in their initial commercial launches. Oxford BioDynamics developed the EpiSwitch SCB non-invasive blood test capable of detecting and distinguishing six common canine cancers including multiple lymphomas, sarcomas, and malignant melanoma with over 89% accuracy, extending blood-based oncology screening capability to the companion animal diagnostics market with a canine-first indication set. Feline testing is expected to register a rapid revenue growth rate in the global companion animal diagnostics market over the forecast period, driven by increasing prevalence of feline chronic kidney disease, hyperthyroidism, and diabetes testing as cat owners pursue diagnostic and wellness services at rates approaching those historically associated with dog ownership.

Based on test type, the global companion animal diagnostics market is segmented into clinical chemistry, immunodiagnostics, hematology, and molecular diagnostics and cytopathology. Clinical chemistry holds the largest revenue share through the established IDEXX Catalyst One and VetLab chemistry analyzer installed base at veterinary clinics processing routine biochemistry panels for wellness examinations, pre-anaesthetic screening, and chronic disease monitoring. Immunodiagnostics and hematology represent the second and third established test categories sharing the premium instrument platform infrastructure. Molecular diagnostics and cytopathology is expected to register the fastest revenue growth rate in the global companion animal diagnostics market over the forecast period, driven by IDEXX inVue Dx slide-free cellular analyzer bringing cytological analysis capability into the in-clinic point-of-care setting, the IDEXX Cancer Dx and Antech Nu.Q Vet Cancer Test launches expanding oncology molecular diagnostic availability, and Zoetis's Vetscan OptiCell AI-powered point-of-care hematology analyzer providing laboratory-quality complete blood count analysis.

Based on regional analysis, the companion animal diagnostics market in North America accounted for largest revenue share in 2025. The United States leads because IDEXX Laboratories and Zoetis are headquartered in the United States, the American Pet Products Association confirms the largest absolute pet-owning household base at nearly 94 million in 2024, and Mars/Antech, Banfield, BluePearl, VCA, and SOUND together represent the deepest owned-clinic diagnostic services infrastructure in the world. IDEXX reported that US Companion Animal Group revenue reached USD 3.57 Billion in 2024 representing 92% of total company revenue, confirming the absolute dominance of the North American companion animal diagnostics market in IDEXX's global revenue base, and the concentration of the inVue Dx and Cancer Dx product launches in the US market first before international availability confirms North America as the primary commercial testing ground for new premium instrument categories.

The market in Europe is expected to register a rapid revenue growth rate over the forecast period. Germany, France, and the United Kingdom represent the three largest national companion animal diagnostics markets within Europe. Mars's September 2024 acquisition of SYNLAB Vet expanded European veterinary diagnostics capabilities with advanced diagnostics, imaging, and telemedicine, representing the most consequential European market consolidation event in companion animal diagnostics during the period. The ongoing Iran-US sanctions and associated Strait of Hormuz maritime disruption through 2026 affect specialty reagent and consumable component supply chains for European veterinary diagnostic product manufacturers, contributing to elevated import costs that add pricing pressure to the European market.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China, Japan, and Australia represent the three largest national companion animal diagnostics markets within the region, with China's rapidly expanding urban pet ownership base representing the largest structural volume growth opportunity in the global companion animal diagnostics market over the forecast period. IDEXX confirmed double-digit international CAG Diagnostics recurring revenue growth throughout 2024 with Asia Pacific as a primary contributor, and the gap between North American per-animal diagnostic testing intensity and the current per-animal testing intensity in China and the broader ASEAN region leaves substantially more room for medicalisation-driven volume growth than exists in any other major regional market.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national companion animal diagnostics markets within the region, with Brazil's private veterinary clinic networks in Sao Paulo and Rio de Janeiro and Mexico's urban veterinary hospital infrastructure in Mexico City and Guadalajara representing the primary commercial diagnostic services deployment sites. The Iran-US sanctions and Strait of Hormuz freight disruption have maintained elevated import costs for veterinary diagnostic instruments, consumables, and assay components entering Brazilian and Mexican distribution networks through 2026, slowing premium instrument placement timelines and increasing per-test reagent costs at regional distributors.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the United Arab Emirates represent the primary commercial companion animal diagnostics markets within the GCC, with growing expatriate and domestic pet-owning populations supporting expanding private veterinary hospital investment across Riyadh, Dubai, and Abu Dhabi. South Africa is the most established market on the African continent for companion animal diagnostics, with Onderstepoort Veterinary Academic Hospital and private veterinary group networks in Johannesburg, Cape Town, and Pretoria representing the primary diagnostic services deployment infrastructure, while the Gulf Cooperation Council states are still building the veterinary specialist capacity and premium instrument installed base density that would drive routine multi-test per visit diagnostic revenue volumes at North American or European standards.